肿瘤药学2024，Vol.14Issue(4)：479-488,10.DOI:10.3969/j.issn.2095-1264.2024.04.15
4种CDK4/6抑制剂用于晚期乳腺癌的安全性网状Meta分析
Safety of four CDK4/6 inhibitors in advanced breast cancer:a network Meta-analysis
摘要
Abstract
Objective To compare and analyze the safety of cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer by using network Meta-analysis.Methods Abemaciclib,palbociclib,ribociclib and dalpiciclib were searched in Chinese and English databases for clinical research on advanced or metastatic breast cancer until June 12,2023.Network Meta-analysis was carried out with ADDIS software to explore the safety differences among the combined endocrine therapy of abemaciclib,palbociclib,ribociclib and dalpiciclib,and the blood toxicity of these drugs was compared and analyzed.Results A total of 14 studies,5 interventions and 6 513 patients were included.The serious adverse events index was ana-lyzed,and the ranking chart showed that the sequence of SAE occurrence probability of each intervention measure from high to low was abemaciclib+endocrine therapy(ET),ribociclib+ET,dalpiciclib+ET,palbociclib+ET,and ET.The order of neutropenia occurrence probability of each intervention measure from high to low was dalpiciclib+ET,palbociclib+ET,ribo-ciclib+ET,abemaciclib+ET,and ET.The order of the occurrence probability of leukopenia of each intervention measure from high to low was dalpiciclib+ET,palbociclib+ET,abemaciclib+ET,ribociclib+ET,and ET.The order of the incidence probability of anemia in each intervention measure from high to low was dalpiciclib+ET,abemaciclib+ET,palbociclib+ET,ribociclib+ET,and ET.The order of the incidence probability of thrombocytopenia of each intervention measure from high to low was palbociclib+ET,dalpiciclib+ET,abemaciclib+ET,ribociclib+ET,and ET.Conclusion The incidence probability of SAE and thrombocytopenia in abemaciclib+ET was higher than that in other CDK4/6 inhibitors.The incidence probability of neu-tropenia,leukopenia and anemia of dalpiciclib+ET was higher than that of other CDK4/6 inhibitors.The incidence probabil-ity of thrombocytopenia of palbociclib+ET was higher than that of other CDK4/6 inhibitors.ET alone had the lowest inci-dence probability of SAE and blood toxicity.The results need to be verified by more high-quality randomized controlled tri-als of head-to-head comparison.Clinicians and pharmacists should use CDK4/6 inhibitors more specifically,and respond positively and effectively to the adverse reactions in time,so as to maximize the efficacy of drugs and reduce the risk of pa-tients' medication.关键词
晚期乳腺癌/阿贝西利/哌柏西利/瑞波西利/达尔西利/网状Meta分析/安全性Key words
Advanced breast cancer/Abemaciclib/Palbociclib/Ribociclib/Dalpiciclib/Network Meta-analysis/Security分类
医药卫生引用本文复制引用
孙彩红,赵俊,韩冰,王心怡,崔萌纳,都彩莹,全香花..4种CDK4/6抑制剂用于晚期乳腺癌的安全性网状Meta分析[J].肿瘤药学,2024,14(4):479-488,10.基金项目
青岛大学附属医院"临床医学+X"科研项目(QDFY+X2023127). （QDFY+X2023127）
